
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. operates within a crucial niche of the medical diagnostics sector, specifically targeting patients with gastroesophageal reflux disease (GERD) who face the risk of developing severe esophageal conditions, positioning the company for substantial market demand. Recent advancements in negotiations with Medicare suggest that favorable coverage decisions could soon enhance broader accessibility and adoption of its flagship products, EsoCheck and EsoGuard. Additionally, Lucid's first mover advantage and the superior efficacy of EsoGuard place the company in a strong position as a potential acquisition target, further bolstering its attractiveness as an investment opportunity.
Bears say
Lucid Diagnostics Inc. reported a pro forma net loss of $9.9 million, or an earnings per share (EPS) of $(0.10), which was slightly worse than company estimates and consensus expectations. Additionally, the volume of EsoGuard tests processed decreased to 2,756 in Q2, marking a decline from previous quarters, indicating potential challenges in product adoption and market penetration. The company's outlook is further complicated by various risks, including balance sheet and liquidity concerns, regulatory hurdles, and intense competition in the biotech and medtech sectors.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares